Positive results from GLP-1 agonist Victoza's (NVO) LEADER cardiovascular outcomes trial (CVOT) were presented at the recent ADA meeting. Soon after the meeting, an FDA advisory committee had a split vote on approving SGLT2 inhibitor Jardiance (Boehringer, LLY) for reducing CV death. Jardiance's sNDA PDUFA is expected in early September.

This infographic highlights US regulatory issues for a CV indication for both drugs, as well as the case for using each of these in various CV and high risk market segments. These considerations may also be pertinent to other drugs in the classes if they likewise have positive outcomes or a class effect becomes apparent.

For our disclosures, please read the Biomedtracker Research Standards.